Selective depletion of B lymphocytes could represent a novel approach to the management of patients with newly diagnosed type 1 diabetes mellitus (T1DM), according to phase II data reported by the ...

The presentation will focus on Vanqua’s development candidate VQ-201, an allosteric small molecule C5aR1 antagonist targeting complement-mediated inflammation associated with peripheral ...

CHICAGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at the 8th Annual Complement-Based Drug Development ...